Xspray Pharma AB (publ)

Stockholm Stock Exchange XSPRAY.ST

Xspray Pharma AB (publ) Free Cash Flow Yield on January 14, 2025: -24.14%

Xspray Pharma AB (publ) Free Cash Flow Yield is -24.14% on January 14, 2025, a -6.21% change year over year. Free cash flow yield compares the return from free cash flow to the market cap; higher yield suggests attractive investment.

Xspray Pharma AB (publ) 52-week high Free Cash Flow Yield is -8.97% on June 12, 2024, which is 62.84% above the current Free Cash Flow Yield.
Xspray Pharma AB (publ) 52-week low Free Cash Flow Yield is -26.36% on January 10, 2025, which is -9.21% below the current Free Cash Flow Yield.
Xspray Pharma AB (publ) average Free Cash Flow Yield for the last 52 weeks is -16.36%.

Key data

Date	Free Cash Flow Yield	Market Value Added (MVA)	Price to Book Ratio (P/B)	Price to Earnings Ratio (P/E)

Stockholm Stock Exchange: XSPRAY.ST

Xspray Pharma AB (publ)

CEO	Dr. Per Andersson Ph.D.
IPO Date	Sept. 28, 2017
Location	Sweden
Headquarters	Råsundavägen 12
Employees	24
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Xspray Pharma AB (publ), a pharmaceutical company, develops protein kinase inhibitors for targeted cancer treatments in Sweden. Its product candidates include HyNap-Nilo for the treatment of chronic myeloid leukemia; HyNap-Sora for the treatment of renal cancer and liver cancer, as well as several forms of thyroid cancer; and HyNap-Dasa for the treatment of chronic myeloid leukemia and acute lymphoblastic leukemia. The company was formerly known as Xspray Microparticles AB and changed its name to Xspray Pharma AB (publ) in 2017. Xspray Pharma AB (publ) was incorporated in 2003 and is based in Solna, Sweden.

Key trends

Past 5 years